A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We were organized as a Delaware corporation in October 2003. On February 14, 2025, we consummated and completed the Merger pursuant to the Merger Agreement, as further described below. Following the consummation of the Merger, NanoVibronix will conduct its operations through its two wholly-owned subsidiaries: (i) NanoVibronix Ltd., a private company incorporated under the laws of the State of Israel (“Nano OpCo”) and (ii) ENvue Medical Holdings LLC, a Delaware limited liability company (together with its respective subsidiaries, “Predecesor ENvue”). Nano OpCo focuses on non-invasive biological response-activating devices that target biofilm prevention, pain therapy, and wound healing and can be administered at home, without the assistance of medical professionals. ENvue is a medical device company engaged in the research, development, production, marketing, and sale of medical devices in the field of enteral feeding and are in the initial stage of commercializing our products.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 2.7M | 2.6M | 2.3M | - | - | - |
| Net Income | -4.6M | - | - | -5.4M | -14M | -4.3M |
| EPS | $-51.59 | $-1,510.30 | $-2,565.20 | $-8,448.00 | $-1,254.00 | $-924.00 |
| Free Cash Flow | -7.3M | -2.5M | -3.6M | -7.0M | -4.4M | -3.4M |
| ROIC | -25.2% | - | - | -658.8% | -52.1% | -45.3% |
| Gross Margin | 30.0% | 59.0% | 67.3% | - | - | - |
| Debt/Equity | 0.02 | 0.19 | 0.00 | 0.03 | 0.01 | 0.10 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -9.4M | -3.6M | -3.4M | -5.0M | -5.7M | -4.7M |
| Operating Margin | -351.8% | -140.0% | -150.5% | - | - | - |
| ROE | -10.8% | - | - | -114.1% | -328.1% | -227.7% |
| Shares Outstanding | 1M | 0M | 0M | 0M | 0M | 0M |
ENvue Medical, Inc. passes 1 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 63.1%.
ENvue Medical, Inc. (FEED) has a 5-year average return on invested capital (ROIC) of -48.7%. This is below average and may indicate limited pricing power.
ENvue Medical, Inc. (FEED) has a market capitalization of $2M. It is classified as a small-cap stock.
ENvue Medical, Inc. (FEED) does not currently pay a regular dividend.
ENvue Medical, Inc. (FEED) operates in the Orthopedic, Prosthetic & Surgical Appliances & Supplies industry, within the Healthcare sector.
ENvue Medical, Inc. (FEED) reported annual revenue of $3 million in its most recent fiscal year, based on SEC EDGAR filings.
ENvue Medical, Inc. (FEED) generated $-3 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
ENvue Medical, Inc. (FEED) has a debt-to-equity ratio of 0.19. This indicates a conservatively financed balance sheet.
ENvue Medical, Inc. (FEED) reported earnings per share (EPS) of $-1510.30 in its most recent fiscal year.
ENvue Medical, Inc. (FEED) has a 5-year average gross margin of 63.1%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 11 years of financial data for ENvue Medical, Inc. (FEED), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
ENvue Medical, Inc. (FEED) has a book value per share of $90.83, based on its most recent annual SEC filing.